Trial Profile
Evaluation of the efficacy and tolerance of Lanreotide LP 90 mg versus placebo in reducing the post lymphorrhoea axillary dissection in breast cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Advanced breast cancer; Cancer metastases
- Focus Pharmacodynamics
- 30 Aug 2011 New trial record